DFO
NRIX icon

Duquesne Family Office’s Nurix Therapeutics NRIX Stock Holding History

Duquesne Family Office’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-44,200
Closed -$993K – 92
2024
Q3 		$993K Hold
44,200
– – 0.03% 73
2024
Q2 		$922K Hold
44,200
– – 0.03% 62
2024
Q1 		$650K Buy
+44,200
New +$475K 0.01% 71

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Duquesne Family Office's NRIX Position: Q4 2024 in Review

Duquesne Family Office sold out of Nurix Therapeutics (NRIX) in Q4 2024, closing a stake of 44,200 shares — an estimated $993K sold.

Duquesne Family Office first reported a position in NRIX in Q1 2024 and held it in 3 quarters. The position peaked at $993K in Q3 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Duquesne Family Office reported no remaining Nurix Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Duquesne Family Office sold 44,200 Nurix Therapeutics shares in Q4 2024, an estimated $993K.
  • Duquesne Family Office first reported a position in Nurix Therapeutics in Q1 2024 and held it in 3 quarters.
  • Duquesne Family Office's Nurix Therapeutics position peaked at $993K in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Duquesne Family Office's 13F filing for Q4 2024, filed 14 Feb 2025.